PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment – OncLive
OncLive |
PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment
OncLive The way forward for the treatment of patients with ovarian cancer will be with novel combination regimens, according to Rebecca C. Arend, MD. For example, bevacizumab (Avastin) is an antiangiogenesis agent that is being combined with many different … |
